Aldeyra to sell 3 million shares in public sale via Cowen, Canaccord

Deal has 15% greenshoe; proceeds to support company’s operations

New York, April 20 – Aldeyra Therapeutics, Inc. is planned to sell 3 million shares of common stock in a public offering via bookrunners Cowen and Co. and Canaccord Genuity.

The deal has a greenshoe for an additional 450,000 shares, according to an S-1 filing with the Securities and Exchange Commission.

Janney Montgomery Scott and Laidlaw & Co. (UK) Ltd. are co-managers.

Proceeds from the sale will be used to support the company’s operations. Specifically, Aldeyra will use funds raised for research and development activities, including current and additional clinical trials of topically administered NS2, to develop systemic formulations of NS2, to develop novel aldehyde traps distinct from NS2, to expand clinical development and regulatory infrastructure, and for working capital and other general corporate purposes. NS2, the company’s most advanced product candidate, is applied to the skin to treat the dermatologic symptoms of Sjögren-Larsson Syndrome, a rare condition that the company believes afflicts approximately 1,000 patients in the United States.

Aldeyra is a Lexington, Mass. biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.